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Abstract
The management of patients with brain metastases has become a major issue due to the increasing frequency 
and complexity of the diagnostic and therapeutic approaches. In 2014, the European Association of Neuro-
Oncology (EANO) created a multidisciplinary Task Force to draw evidence-based guidelines for patients with 
brain metastases from solid tumors. Here, we present these guidelines, which provide a consensus review of 
evidence and recommendations for diagnosis by neuroimaging and neuropathology, staging, prognostic fac-
tors, and different treatment options. Specifically, we addressed options such as surgery, stereotactic radio-
surgery/stereotactic fractionated radiotherapy, whole-brain radiotherapy, chemotherapy and targeted therapy 
(with particular attention to brain metastases from non–small cell lung cancer, melanoma and breast and renal 
cancer), and supportive care.
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Brain metastases represent a common neurological com-
plication of systemic cancer and are an important cause of 
morbidity and mortality.
Brain metastases are the most frequent intracranial 
tumors: the incidence of newly diagnosed brain metasta-
ses is 3–10 times the incidence of newly diagnosed primary 
malignant brain tumors.1 The incidence of brain metastases 
has increased over time, as a result of increasing use of neu-
roimaging and improvement in the treatment of systemic 
disease.
The majority of patients who develop brain metasta-
ses have a limited life expectancy, as the appearance of 
the disease in the brain is frequently a hallmark of dis-
seminated end stage disease, but patients with a lim-
ited disease may have a more favorable outcome with 
the use of intensive therapies. Knowledge of the most 
powerful prognostic factors (Karnofsky performance 
status [KPS], age, extracranial tumor activity, number 
of brain metastases, primary tumor type/molecular sub-
type) is crucial for predicting individual prognosis. In this 
regard, several prognostic indices have been developed 
in order to distinguish subgroups of patients with differ-
ent outcomes.2,3
The objective of this guideline is to provide clinicians 
with evidence-based recommendations and consensus 
expert opinion for the management of adult patients with 
brain metastases from solid tumors.
The search strategy and selection criteria for review-
ing the literature evidence can be found in Table 1. 
Recommendations can ben found in Tables 2–6.
Diagnostic Approach
Diagnosis by neuroimaging, staging, and diagnostic neu-
ropathology have been reviewed but not graded. These 
sections can be found in the Supplementary material.
Treatment of Newly Diagnosed Brain 
Metastasis
Surgery
Three phase III trials have compared surgical resection fol-
lowed by whole-brain radiotherapy (WBRT) to WBRT alone 
in patients with single brain metastases.4–6
The first 2 studies, both of which were underpowered, 
reported a survival benefit for patients receiving the com-
bined treatment (median survival 10 mo vs 4–6 mo). In 
Patchell’s study, 4 patients who received surgery had a 
lower rate of brain relapses (20% vs 52%) and a longer 
time of functional independence. The third study, which 
Importance of the study
This manuscript reports the evidence-based guidelines 
on management of brain metastases developed by a 
multidisciplinary task force of the EANO, composed of 
medical experts from 10 European countries, includ-
ing neurologists, neurosurgeons, radiation oncolo-
gists, medical oncologists, neuroradiologists, and 
neuropathologists. These guidelines should aid all 
professionals involved in the management of patients 
with brain metastases in the daily clinical practice, and 
could also serve as a source of knowledge for institu-
tions and insurance companies involved in cancer care 
in Europe.
Table 1 Search strategy and selection criteria
• A Task Force was appointed in 2014 by the European Association of Neuro-Oncology (EANO) to draw guidelines on the 
management of brain metastases from solid tumors. The Task Force was composed of medical experts from 10 European countries,  
including neurologists, neurosurgeons, radiation oncologists, medical oncologists, neuroradiologists, and neuropathologists.
• References were identified through searches of PubMed, using specific and sensitive keywords, as well as combinations of 
keywords. Abstracts presented at American Society of Clinical Oncology in 2014 and 2015 were considered as well when relevant. 
When available, we also collected existing guidelines from national multidisciplinary neuro-oncological societies. The final 
reference list was generated on the basis of originality and relevance to the scope of this review. The last update on PubMed was on 
July 15, 2016.
• Scientific evidence was assessed and graded according to the following categories: class I evidence was derived from randomized 
phase III clinical trials; class IIa evidence derived from randomized phase II trials; class IIb evidence derived from single arm phase 
II trials; class IIIa evidence derived from prospective studies, including observational studies, cohort studies, and case-control 
studies; class IIIb evidence derived from retrospective studies; and class IV evidence derived from uncontrolled case series, case 
reports, and expert opinions.
• To establish recommendation levels, the following criteria were used: level A required at least one class I study or 2 consistent 
class IIa studies; level B required at least one class IIa study or several class IIb and III studies; level C required at least 2 
consistent class III studies. When there was insufficient evidence to categorize recommendations in levels A–C we classified the 
recommendations as a Good Practice Point, if agreed by all members of the task force.
• When drawing recommendations, at any stage, the differences were resolved by discussions and, if persisting, were reported in the 
text.
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included more patients with an active systemic disease 
(80% vs 30%–40%) and a lower KPS, did not show benefit 
with the addition of surgery to WBRT.6 However, a consid-
erable fraction of patients assigned to WBRT alone actually 
crossed over to receive surgery, and this may have con-
tributed to similar survival between the 2 treatment arms. 
None of the patients had pretreatment MRI scans, thus 
inclusion of patients with multiple brain metastases could 
not be excluded. Overall, the study was poorly designed 
and executed, making it less informative. In summary, 
there is limited class I evidence for survival benefit of sur-
gical resection in addition to WBRT, and this is likely to be 
restricted to the subgroup of patients with controlled sys-
temic disease and good performance status.
Surgical resection allows in the majority of patients an 
immediate relief of symptoms of intracranial hypertension, 
a reduction of focal neurological deficits and seizures, and a 
rapid steroid taper. Gross total resection of a brain metasta-
sis can be achieved with lower morbidity using contempo-
rary image guided systems, such as preoperative functional 
MRI, intraoperative neuronavigation, and cortical mapping 
(class  IV).7 An early postoperative MRI has been reported 
to detect residual tumor in up to 20% of patients, and the 
presence of residual tumor has been associated with an 
increased risk of local recurrence (class IIIb).8
The impact of surgical techniques on the complication 
rate and functional outcome as well as on the risk of local 
relapse in patients with single brain metastasis has been 
recently reviewed (class  IIIb).9 Leptomeningeal dissemi-
nation can be a complication, especially in patients with 
posterior fossa metastases undergoing a “piecemeal” 
resection (13.8%) compared with “en bloc” resection (5%–
6%) (class IIIb).10
In patients with 2 or 3 brain metastases, who have a high 
performance status and controlled systemic disease, com-
plete surgical resection yields results that are comparable 
to those obtained in single lesions (class IIIb).11
Stereotactic Radiosurgery
Stereotactic radiosurgery (SRS) is a high precision local-
ized irradiation given in one fraction using a combination 
of firm immobilization and image guidance. Convergence 
of multiple static or moving beams achieves a steep dose 
fall-off from the target to the surrounding normal struc-
tures, allowing for a high dose to the tumor with low risk of 
damage to surrounding normal brain. Small brain metas-
tases represent an ideal target for SRS, owing to the gener-
ally spherical shape and distinct pathologic margins.12 The 
dose is inversely related to tumor size. Maximal tolerated 
doses of SRS have been described in the Radiation Therapy 
Oncology Group (RTOG) 9005 study,13 which included het-
erogeneous groups of patients with previously irradiated 
primary brain tumors and brain metastases. The suggested 
doses were 24 Gy for ≤20 mm, 18 Gy for 21–30 mm, and 
15 Gy for 31–40 mm in maximum diameter lesions. High 
single radiation doses to large tumors or tumors close to 
critical neural structures are associated with significant 
risk of toxicity, and there are attempts at employing hypo-
fractionated regimens to achieve adequate local control 
with acceptable toxicity. However, randomized studies 
comparing stereotactic fractionated radiotherapy (SFRT) 
versus single dose SRS are lacking.
Single dose SRS in the treatment of a limited number 
(1–3) of newly diagnosed brain metastases has yielded 
a local control (defined as shrinkage or arrest of growth) 
at 1  year of 80%–90% with symptoms improvement and 
median survival of 6–12 months (class IIIa).14 Patients with 
a single lesion, controlled extracranial disease, and KPS of 
70% or greater have longer survival.15,16 Metastases from 
radioresistant tumors, such as melanoma and renal cell 
carcinoma, respond to SRS as do metastases from radio-
sensitive tumors.17 Older patients (≥80 y) respond as well 
as younger patients.18 The outcome following gamma-knife 
or linear accelerator (Linac)–based procedures is similar.
A randomized phase III study (RTOG 9508)  in patients 
with 1–3 brain metastases, stratified by the recursive par-
titioning analysis prognostic classification, investigated 
the value of the addition of an SRS boost to WBRT19 and 
reported better local control and performance status at 
6  months in the combined therapy group (class  I); how-
ever, the survival advantage was only demonstrated in 
patients with single metastasis (6.5 mo vs 4.9 mo). A sec-
ondary analysis of RTOG 9508 that retrospectively strati-
fied patients with the graded prognostic assessment (GPA) 
classification, suggested that the addition of SRS to WBRT 
confers a significant survival benefit for patients with a 
good prognosis (GPA 3.5–4.0) regardless of whether they 
had 1, 2, or 3 brain metastases.20 Conversely, this ben-
efit did not extend to patients with lower GPA and/or 2–3 
metastases.
In the past 5–10 years SRS has been increasingly used 
for patients with higher number of brain metastases, 
due to improved technology that allows the delivery of 
SRS with increasing speed while maintaining precision 
and accuracy. A  prospective multicenter Japanese study 
investigated the use of SRS alone in 1194 patients with 1, 
2 to 4 or 5 to 10 brain metastases, and found similar over-
all survival (OS) (10.8 mo) and treatment-related toxicity 
rates between the groups with 2 to 4 and 5 to 10 metasta-
ses (class IIIa).16 Cumulative volume of metastases, rather 
than the number, was reported as a significant prognostic 
factor.16
Early, early delayed, and late complications following 
radiosurgery are reported in 10%–40% of patients, but 
serious complications are rare,21 although this may be a 
function of limited follow-up. Acute reactions presumed to 
be due to edema can occur within 2 weeks of treatment 
and consist of headache, nausea and vomiting, worsen-
ing of preexistent neurological deficits, and seizures. 
These reactions are generally reversible with steroids. Late 
complications (months to years) consist of hemorrhage 
and radionecrosis and have been reported in 1%–17% of 
patients. Following SRS, treatment-related changes—such 
as increase of contrast enhancement, necrosis, edema, and 
mass effect on MRI—are difficult to distinguish from tumor 
progression: in this regard, PET with 2-fluoro-2-deoxy-
d-glucose or amino acids, MRI perfusion, and MR spectros-
copy may provide additional information, though they are 
rarely diagnostic.22
Radiation necrosis is commonly treated with steroids. 
Hyperbaric oxygen and/or the anti–vascular endothe-
lial growth factor agent bevacizumab, which may allow 
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stabilization/normalization of the vascular permeability, 
can be useful in patients not responding to steroids.23 
Surgical resection is needed in some patients.
The risk of adverse radiation effects following SRS has 
been reported to increase with the increase of size of 
lesions with a 1-year cumulative incidence of 13%–14%.24 
A wide range in the time of onset and time to improvement 
of these effects was observed.
There are no reports in the literature on the treatment of 
brain metastases with proton radiosurgery.25
Surgery vs Stereotactic Radiosurgery
Most studies comparing surgery and SRS report similar 
outcomes; however, they are not randomized and are likely 
to be affected by selection bias (class IIIb).26–28
SRS is considered less invasive, can be carried out in an 
outpatient setting, and is more cost-effective than surgery. 
Patients with larger lesions may require chronic steroid 
administration.
Whole-Brain Radiotherapy Following Surgery or 
Stereotactic Radiosurgery
There has been a long debate as to whether adjuvant 
WBRT, whose rationale is that of destroying microscopic 
disease at the original tumor site or at distant intracranial 
locations, is necessary after complete surgical resection or 
radiosurgery of a limited number of brain metastases.29,30
Three large phase III trials31–33 and a meta-analysis34 
have been carried out. They demonstrated that the omis-
sion of WBRT in patients with a limited number of brain 
metastases after either complete surgery or SRS results in 
significantly worse local and distant control in the brain, 
but does not affect functionally independent and overall 
survival (class I). The American31 and the Japanese32 trials 
included patients with both stable and progressive sys-
temic disease, while the European trial33 was restricted 
to patients with stable systemic disease, that is, those 
who could maximally benefit in terms of survival from 
improved intracranial control. A  recent individual patient 
data meta-analysis of 3 randomized trials comparing SRS 
alone with SRS + WBRT in patients with 1 to 4 brain metas-
tases35 suggested a survival advantage for SRS alone in 
patients aged <50 years without a reduction in the risk of 
new brain metastases with adjuvant WBRT; conversely, in 
patients aged >50 years WBRT decreased the risk of new 
brain metastases but did not affect survival. A secondary 
analysis of the Japanese trial has retrospectively strati-
fied patients by GPA score and suggested that a subgroup 
of patients with non–small cell lung cancer (NSCLC) with 
higher GPA scores (2.5–4.0) have a survival benefit from 
SRS + WBRT compared with SRS alone (median survival 
16.7 vs 10.7 mo).36 These are exploratory hypotheses, 
which require further studies.
Adjuvant WBRT following surgery reduces local and dis-
tant recurrences in the brain among patients with metasta-
ses >3 cm and/or active systemic disease (class IIIb).37
The impact of adjuvant WBRT on cognitive functions and 
quality of life has been analyzed in few studies. Aoyama 
et al38 compared the neurocognitive function of patients 
who underwent SRS alone or SRS + WBRT. More than 
50% of patients experienced a significant improvement in 
Mini-Mental State Examination score shortly after therapy 
(2–3 mo) regardless of which treatment they had initially 
received, with subsequent deterioration of neurocognitive 
function in long-term survivors (up to 36 mo) after WBRT. 
Chang et al39 in a small randomized trial have shown that 
patients treated with SRS plus WBRT were at greater risk 
of a decline in learning and memory function at 4 months 
after treatment compared with those receiving SRS alone.
A randomized phase III trial (Alliance trial) has compared 
SRS alone versus SRS + WBRT in patients with 1–3 brain 
metastases using a primary neurocognitive endpoint, 
defined as decline from baseline in any 6 cognitive tests at 
3 months.40 The decline was significantly more frequent after 
SRS + WBRT versus SRS alone (88% vs 61.9%) (class I) with 
more deterioration in immediate recall (31% vs 8%), delayed 
recall (51% vs 20%), and verbal fluency (19% vs 2%). A qual-
ity of life analysis of the European Organisation for Research 
and Treatment of Cancer (EORTC) 22952-26001 trial has 
shown over 1 year of follow-up no significant differences in 
global health related quality of life, but patients undergoing 
adjuvant WBRT had transient lower physical functioning and 
cognitive functioning scores and more fatigue (class I).41
Based on the results of these trials, the American Society 
for Radiation Oncology (ASTRO) has recommended in its 
Choose Wisely campaign not to routinely add adjuvant 
WBRT to SRS for patients with limited number of brain 
metastases.
The issue of the need of WBRT following surgical resec-
tion is less well defined, as randomized trials reported an 
increased risk of local relapse following surgery alone, 
though it remains unclear whether an active surveillance 
with salvage local therapy is as effective as an early addi-
tional treatment in the form of WBRT.
Stereotactic Radiosurgery/Stereotactic 
Fractionated Radiotherapy Following Surgery
Postoperative SRS is an approach to decrease the local 
relapse following surgery while avoiding the cognitive 
sequelae of WBRT. Several retrospective42–44 and one 
prospective phase II trial45 reported local control rates at 
1  year around 80% (70%–90%) and a median survival of 
10–17  months (class  IIIa): this suggests that postopera-
tive SRS is as effective as WBRT in achieving local control. 
An alternative approach is the use of SFRT, presumed to 
be associated with lower risk of radionecrosis in larger 
lesions.44,46
The balance between risk and benefit is currently 
unknown with unsolved issues, such as the optimal dose 
and fractionation and the effects on survival, quality of life, 
and cognitive function. Randomized trials are ongoing.
The risk of radionecrosis following postoperative SRS 
seems higher (9%–17.5%)47,48 than that reported by the 
EORTC study with WBRT following either surgery or radio-
surgery (2.6%), and could increase over time (7% at 1 y and 
16% at 2 y).
There is lack of information on the clinical counterparts of 
radionecrosis and on the incidence of acute complications 
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of SRS, such as seizures, headache, and hemorrhage. One 
of the risks following SRS is the steroid dependency to con-
trol chronic edema: so far, neither frequency nor duration of 
steroid use following postoperative SRS has been analyzed.
SRS to the resection cavity is associated with a risk of 
leptomeningeal relapse in 8% to 13% of patients,49,50 
especially with breast histology (at 1 y 24% vs 9%): it is 
unknown whether the use of WBRT would decrease the 
risk of leptomeningeal relapse.
In conclusion, there is currently no high level of evi-
dence in favor of SRS/SFRT following surgery of brain 
metastases.51
Whole-Brain Radiotherapy
Overall, in the different studies of the past, a response fol-
lowing WBRT has been reported in up to 60% of patients; 
however, the neurological improvement could be partially 
attributable to steroids. Tumor volume reduction after 
WBRT has been associated with better neurocognitive 
function and prolonged survival.52 Median survival follow-
ing WBRT alone in patients with multiple brain metastases 
ranges from 3 to 6 months, with 10%–15% of patients alive 
at 1 year. A meta-analysis of 39 trials has concluded that 
altered WBRT dose fractionation schemes are not superior 
in terms of OS, neurologic function, or symptom control 
as compared with standard fractionation (30 Gy in 10 frac-
tions or 20 Gy in 5 fractions) (class I).53 A recent phase III 
non-inferiority trial in patients with brain metastases from 
NSCLC, not a candidate for either surgery or radiosurgery, 
has not shown differences in OS and quality of life between 
WBRT and supportive care (class I).54
To date, radiosensitizers have not provided any clear 
additional benefit over conventional radiotherapy.
Mild to severe cognitive dysfunctions occur following 
WBRT, and new approaches (neuroprotective drugs, new 
techniques of radiotherapy) are being developed in order 
to minimize the potential negative impact of WBRT.
In a randomized double-blind, placebo-controlled phase 
III trial (RTOG 0614)  the use of memantine, a neuropro-
tective compound, during and after WBRT has resulted in 
better cognitive function over time, specifically delaying 
time to cognitive decline and reducing the rates of decline 
in memory, executive function, and processing speed 
(class  IIa).55 Hippocampal avoidance WBRT using inten-
sity modulated radiotherapy to reduce the radiation dose 
to the hippocampus56 is not associated with increased 
risk of recurrence in the low dose region.57 A single arm 
phase II trial (RTOG 0933) has suggested that hippocampal 
avoidance may be associated with some sparing of WBRT-
induced memory deficit and quality of life (class IIb),58 but 
these findings need confirmation in randomized trials cur-
rently under way.
Treatment of Recurrent Brain 
Metastases
Reoperation has been suggested to yield a neurologi-
cal improvement and prolongation of survival in patients 
with locally accessible brain relapse, high performance 
status, stable extracranial disease, and relatively long 
time to recurrence (>6 mo) (class IIIb).7 Salvage SRS after 
WBRT has been widely used (class IIIb).59–61 In a large ret-
rospective series,61 the median times to in-field and dis-
tant brain failure from salvage SRS were 14 months and 
11.7 months, respectively, with a median time to CNS death 
of 9.31 months.
Reirradiation with SRS after local recurrence of an initial 
SRS has been employed in a limited number of patients, 
and the risk of long-term radionecrosis should be balanced 
against the potential but unproven clinical benefit.62
Multiple courses of SRS for new brain metastases after 
an initial course of SRS with continued deferral of WBRT 
could yield high rates of local control, low risk of toxic-
ity, and favorable duration of overall and neurologic pro-
gression-free survival (PFS).63 A recent large retrospective 
series has reported that in patients undergoing multiple 
courses of SRS, the aggregate volume, but not the cumu-
lative number of brain metastases, and the GPA score, as 
recalculated at the second course of SRS, correlate with 
duration of survival (class IIIb).64
Chemotherapy and Targeted Therapies
General Considerations
The level of evidence of studies on chemotherapy of brain 
metastases from solid tumors is class  IIIa–b.65 Response 
rates reflect the sensitivity of the primary tumor: rela-
tively high response rates in small cell lung cancer (30%–
80%), intermediate rates in breast cancer (30%–50%) and 
NSCLC (10%–30%), and low rates in melanoma (10%–15%); 
response in the brain does not always parallel that at the 
extracranial sites; the response to chemotherapy from 
most chemosensitive tumors could be of the same order 
as that observed after radiotherapy.
The association of radiotherapy and chemotherapy may 
improve response rates compared with radiotherapy alone 
but does not improve survival.
As for targeted therapies and immunotherapy, due to the 
increasing number of reports in the recent literature, the 
review and grading of evidence were restricted to clinical 
trials focused on brain metastases (mainly phase II trials).
Overall, the response rates of brain metastases to tar-
geted agents in the different molecular subtypes seem 
higher than those observed after cytotoxic chemotherapy. 
However, the majority of targeted agents that have been 
investigated so far are small molecules, such as the first 
generation of tyrosine kinase inhibitors (TKIs), with a lim-
ited penetration of the blood–brain barrier (BBB), as they 
are substrates of active efflux transporters. Changing the 
schedule and/or regimen of administration (for instance, 
pulsatile dosing of the epidermal growth factor receptor 
[EGFR] inhibitor erlotinib) could increase the efficacy. Two 
factors limit the impact of the available targeted agents on 
brain metastases: an unpredictable lack of molecular con-
cordance between the primary tumor and the brain metas-
tases, and the rapid emergence of a secondary resistance, 
which can occur systemically but not necessarily in the 
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CNS. To overcome all these limitations, several second- 
and third-generation small-molecule inhibitors are being 
investigated.
Last, there are numerous reports on the combination of 
immunotherapy and targeted therapies with SRS, but the 
literature on this issue is still too sparse.66,67 In this regard, 
an increased risk of radionecrosis following SRS and 
immunotherapy has been suggested.68
Brain Metastases from NSCLC
Platinum compounds (cisplatin, carboplatin), alone or in 
combination with other agents (etoposide, vinorelbine, 
pemetrexed), are the most commonly used chemothera-
peutics in the management of disseminated NSCLC and 
have been employed in the setting of brain metastases, 
either upfront or at recurrence after radiotherapy.65 The 
activity in terms of response rate is similar to that expected 
in the systemic setting and is higher in chemo-naïve 
patients.
Targeted agents in patients with sensitizing EGFR and 
anaplastic lymphoma kinase (ALK) mutations have shown 
activity. Response rates of brain metastases to EGFR TKI 
treatment (gefinitib, erlotinib, and afatinib) in patients with 
NSCLC harboring EGFR mutations reach 60%–80%, with 
rates of complete responses as high as 40%. Median OS is 
in the range of 15–20 months, and PFS in the brain is about 
6.6–11.7  months, both significantly longer than for EGFR 
wild-type tumors.69
Based on the high intracranial response rates, TKIs alone 
have been proposed as initial treatment instead of WBRT in 
patients harboring activating EGFR mutations and asymp-
tomatic brain metastases,70–72 although this approach could 
be associated with a higher risk of subsequent intracra-
nial relapse. The use of primary TKIs can avoid the adverse 
effects of WBRT, although it is unlikely to avoid the need 
for subsequent WBRT. An alternative strategy is the use of 
cranial radiotherapy (SRS or WBRT) in combination with 
TKIs, which may improve PFS and OS compared with 
TKIs alone or radiotherapy with or without chemotherapy, 
although this is somewhat controversial and remains to be 
proven (class  IIIa and b).73,74 A phase II study from China 
has reported that the combination of WBRT and erlotinib 
has tolerable toxicities, and suggested a prolonged PFS 
and OS (class  IIb).75 Conversely, phase II (class  IIa and 
b)76,77 and phase III (class I)78 trials in patients with NSCLC 
brain metastases not enriched for EGFR mutations failed to 
demonstrate a superiority of the combination of erlotinib 
with either SRS or WBRT over radiotherapy alone, with a 
suggestion of worse outcome in patients receiving the 
combined therapy. A Chinese phase II trial of WBRT with 
concurrent icotinib, another EGFR inhibitor, has suggested 
that the combination could improve survival compared 
with historical controls.79
Other druggable alterations in NSCLC patients are the 
rearrangements of the ALK gene that seem to be constant 
between brain metastasis and primary tumor.80 NSCLC 
with ALK activating translocations is sensitive to treatment 
with the ALK inhibitor crizotinib. In a retrospective analy-
sis of the clinical trial PROFILE, crizotinib has been associ-
ated with 55% intracranial control at 3 months of therapy in 
patients with ALK-rearranged NSCLC who were ALK inhibi-
tor naïve and had brain metastases.81 Crizotinib yielded 
18%–33% responses using RECIST (Response Evaluation 
Criteria in Solid Tumors), and the efficacy was observed 
among both radiotherapy-naïve and preirradiated patients 
(class IIIb). Responses are generally short-lived, and most 
patients need subsequent WBRT. Whether WBRT should be 
employed immediately after crizotinib response or after 
progression is still unclear. A recent multi-institutional ret-
rospective analysis has suggested that patients with brain 
metastases from ALK-rearranged NSCLC receiving radio-
therapy (SRS and/or WBRT) and ALK inhibitors (crizotinib, 
ceritinib, alectinib) have a prolonged OS (around 49.5 mo) 
(class IIIb).82
Some efficacy with acceptable safety has been sug-
gested in a phase II study of patients with asymptomatic 
untreated brain metastases from NSCLC with bevacizumab 
in combination with paclitaxel and carboplatin (class IIb).83
A recent early analysis of a phase II trial of the pro-
grammed cell death protein 1 inhibitor pembrolizumab has 
shown activity in untreated or previously irradiated brain 
metastases from NSCLC,84 but the trial is still ongoing.
Brain Metastases from Breast Cancer
Chemotherapy regimens, variably combining capecit-
abine, cyclophosphamide, 5-fluorouracil, methotrexate, 
vincristine, cisplatin, and etoposide, are active in patients 
with brain metastases from breast cancer.65
The dual EGFR and human epidermal growth factor 
receptor (HER)2 TKI lapatinib has shown modest activity in 
a phase II study in HER2+ breast cancer patients with brain 
metastases following trastuzumab-based systemic chemo-
therapy and WBRT (class IIb).85 CNS objective responses to 
lapatinib were observed in 6% of patients, and 21% expe-
rienced ≥20% volumetric reduction in the CNS lesions. 
Another phase II single arm study (LANDSCAPE) has 
shown that the association of lapatinib and capecitabine 
in patients with radiotherapy-naïve brain metastases 
from HER-positive metastatic breast cancer yields dura-
ble responses in up to 65% of patients (class IIb).86 A sin-
gle arm phase II trial on neratinib (HER2 TKI) in patients 
with brain metastases previously treated with either WBRT 
or SRS has shown a response rate of 8% with an OS of 
8.7 months (class IIb).87
Due to a lack of prospective trials, it is not clear whether 
trastuzumab, which probably can cross a more permeable 
BBB within established brain metastases, can be active as 
well.88 Several case reports and small patient series indi-
cate that the antibody-drug conjugate T-DM1 (trastuzumab 
emtansine) may be active against brain metastases of 
HER2+ breast cancer (class IV).89,90 Few data only are avail-
able on the combination of different anti-HER2 agents. 
There are no reliable data on the efficacy of endocrine 
therapies.
Brain Metastases from Melanoma
Fotemustine (response rate of 5%–25%) and temozolo-
mide (response rate 6%–10%), either as single agent or in 
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combination with WBRT, are active agents against brain 
metastases from melanoma.65,91
Ipilimumab is a human monoclonal antibody directed 
against cytotoxic T-lymphocyte-associated protein 4 that 
potentiates the antitumor immune response. Despite the 
fact that ipilimumab does not cross the BBB, the activa-
tion of the immune system and the migration of lympho-
cytes into the brain allow an antitumor effect also in the 
brain parenchyma.92 In a phase II study of ipilimumab in 
metastatic melanoma, 12 of 115 patients had brain metas-
tases at enrollment.93 Two of these patients achieved partial 
response (PR) and 3 had stable disease (SD). Both patients 
with PR and one with SD had an OS of over 4 years. In a 
retrospective analysis of 38 patients with brain metastases 
treated within the French Expanded Access Program (EAP), 
3 had PR and 5 SD, and 1-year survival was 10.5%.94 An 
open-label, single arm phase II trial included 2 cohorts of 
patients: 51 patients with asymptomatic brain metastases 
(cohort A) and 21 patients with symptomatic brain metas-
tases controlled with corticosteroids (cohort B) (class IIb).95 
Disease control (complete response [CR]+PR+SD) after 
12 weeks was 26% in cohort A and 10% in cohort B, with 
median OS of 7.0 months and 3.7 months, respectively. The 
response rates were similar for intra- and extracranial dis-
ease in both cohorts, and neurological toxicity was mainly 
of grades 1–2. A  single arm phase II study, NIBIT-M1, 
treated 86 patients with ipilimumab and fotemustine, of 
whom 20 had asymptomatic brain metastases at baseline, 
mostly oligometastases96: 10 of these patients achieved 
disease control, and median PFS and OS were 4.5 months 
and 13.4 months, respectively. In an EAP study of stages 3 
and 4 melanoma and asymptomatic brain metastases fail-
ing or not tolerating other treatments,97 ipilimumab yielded 
a control rate of 27%, including 4 patients with CR and 13 
with PR. Median PFS and OS were 2.8 and 4.3  months, 
respectively, and approximately one-fifth of patients were 
alive 1 year after starting ipilimumab.
Chemotherapy96 or radiotherapy98 could induce a release 
of tumor antigens, thus increasing the antitumor activity of 
ipilimumab. An abscopal effect has been seen in melanoma 
patients, in whom radiotherapy for one lesion induced a 
shrinkage of non-irradiated lesions.99 Sequence and tim-
ing of radiotherapy in relation to ipilimumab have not been 
fully elucidated.100,101 To sum up, immunotherapy with ipili-
mumab has activity in brain metastases from melanoma, 
and the effects seem similar in intra- and extracranial dis-
ease. In patients with symptomatic brain metastases, the 
effect is smaller, maybe due to corticosteroid treatment 
or alternatively the generally worse prognosis. An activ-
ity of programmed cell death protein 1 inhibitors, such as 
pembrolizumab and nivolumab, in brain metastases from 
melanoma has been suggested.84,102
Mutations of v-raf murine sarcoma viral oncogene 
homolog B1 (BRAF) occur in approximately 50% of 
melanomas, resulting in a constitutive activation of the 
mitogen-activated protein kinase pathway, and BRAF 
Table 2 Recommendations at diagnosis
• When neurological symptoms and/or signs develop in a patient with known solid cancer, brain metastasis must always be sus-
pected (Good Practice Point).
• Contrast-enhanced MRI is the method of choice for assessment of brain metastases. A differential diagnosis between brain 
metastases and primary brain tumors (especially malignant gliomas and primary CNS lymphomas) and nonneoplastic conditions 
(abscesses, infections, vascular diseases) must be considered, even in patients with history of solid cancer and/or multiple lesions 
(Good Practice Point).
• Diffusion-weighted MR imaging is useful to differentiate among ring-enhancing lesions brain metastases from pyogenic 
abscesses (level C).
• Advanced neuroimaging techniques, such as MRI perfusion, MR spectroscopy, PET with FDG [2-fluoro-2-deoxy-d-glucose] or 
amino acids, do not provide sufficient differentiation among enhancing lesions between brain metastases and other malignant 
brain tumors of glial or non-glial origin (Good Practice Point).
• In case of known primary tumor, systemic staging should include all the assessments required for the specific tumor type in order 
to define the activity of the primary lesion and the existence of extra cranial metastases (Good Practice Point).
• In case of unknown primary tumor, a thorough physical examination (including testes and skin inspection), CT of the chest/abdo-
men, and mammography and/or ultrasound of breast are recommended and, if negative, whole body FDG PET is recommended 
(Good Practice Point).
• A tissue diagnosis is mandatory in patients with suspected brain metastasis on MRI and unknown primary tumor after a systemic 
workup before any treatment is undertaken (Good Practice Point).
• A tissue diagnosis should be considered in patients with well-controlled systemic cancer when the neuroimaging appearance is 
atypical and/or a long interval has elapsed since the initial cancer diagnosis (Good Practice Point).
• Routine hematoxylin-eosin stain of the biopsy specimen usually is sufficient for a correct histological diagnosis. 
Immunohistochemical markers are required when the basic morphology is equivocal and/or the primary tumor is unknown in 
order to suggest the site of origin (Good Practice Point).
• Molecular markers that influence treatment decisions (predictive markers) should be assessed from brain metastasis tissue, if 
available, even when the respective marker(s) have already been assessed from tissue samples from extracranial tumor manifes-
tations (Good Practice Point).
• CSF biochemistry and cytology are needed when a coexistent leptomeningeal involvement is suspected (Good Practice Point).
• Before treatment, patients should be assessed according to one of the existing prognostic scores (with preference for GPA score) 
(Good Practice Point).
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mutation status is usually concordant between extrac-
ranial tumor and brain metastasis.103 The BRAF inhibitor 
vemurafenib has documented activity in brain metasta-
ses from BRAF-mutated melanomas.104 An open-label 
pilot study included 24 patients with BRAF-mutated 
advanced melanoma and symptomatic brain metas-
tases (class  IIIa).105 All patients were on corticosteroids 
for symptom control, and had progressed after previous 
surgery or radiotherapy. Of 19 patients with measurable 
intracranial disease, 3 had a PR and 13 an SD. Median 
duration of response in the brain was 4.4  months with 
median OS of 5.3  months. In a retrospective review 
of 22 patients with asymptomatic brain metastases 
(class  IIIb),106 a 50% response rate was seen regardless 
of whether they had previous local therapy to the brain 
or not, and clinical benefit was reported for two-thirds 
of patients. Median time to progression and median OS 
were 23 and 46 weeks, respectively, for patients with 
objective response, and 12 weeks and 21 weeks for 
patients without objective response.
Two studies are available on the other BRAF inhibi-
tor, dabrafenib. A phase I study included 10 patients with 
asymptomatic, untreated brain metastases; 9 achieved 
a decrease in the size of brain lesions and 4 achieved CR 
(class IIIb) with a median PFS of 4.2 months.107 
The multicenter, open-label, phase II BREAK-MB trial 
enrolled 172 patients with asymptomatic, untreated 
(cohort A) or progressive (cohort B) brain metastases in 
melanoma patients with V600E or V600K mutation for 
treatment with dabrafenib (class  IIb).108 Over 80% of 
patients in both cohorts with V600E mutations had intrac-
ranial disease control (CR+PR+SD), median PFS was 
longer than 16 weeks in both cohorts, and OS exceeded 
31 weeks.The combination of BRAF inhibitors and SRS 
could improve survival,109,110 but an increase of toxicities 
Table 3 Recommendations regarding treatment of newly diagnosed brain metastases
• Surgical resection should be considered in patients with a limited number (1 to 3) of newly diagnosed brain metastases, especially 
in case of lesions of ≥3 cm in diameter (symptomatic or not), lesions with necrotic or cystic appearance and edema/mass effect, 
lesions located in the posterior fossa with associated hydrocephalus, and lesions located in symptomatic eloquent areas (Good 
Practice Point).
• Surgical resection is recommended when the systemic disease is absent/controlled and the KPS is 60 or more, as it can prolong 
survival (level A).
• Surgical resection can be an option when the systemic disease is active but effective systemic treatment options are available or 
when the primary tumor is relatively radioresistant (ie, melanoma, renal carcinoma, colon carcinoma) (Good Practice Point).
• Stereotactic radiosurgery should be considered in patients with metastases of a diameter of ≤3–3.5 cm (level B).
• Stereotactic fractionated radiotherapy (SFRT) should be considered in patients with metastases larger than 3 cm in maximum 
diameter and a larger irradiation volume than 10 or 12 cm3 due to increased toxicity and radiation necrosis of normal brain tissue 
(Good Practice Point).
• Stereotactic radiosurgery and/or stereotactic fractionated radiotherapy should be considered in patients with metastases that are 
not resectable due to location (ie, basal ganglia, brain stem, eloquent cortical areas) or with comorbidities precluding surgery (ie, 
older age, cardiovascular disease, etc) (Level C).
• When both surgical resection and SRS/SFRT are feasible, the choice should be made on a case-by-case basis with consideration 
given to tumor size, site, type of neurological symptoms, need for steroids, patient preference, and/or physician expertise (Good 
Practice Point).
• Following complete surgical resection or SRS for a limited number of brain metastases, adjuvant WBRT is not unequivocally rec-
ommended due to lack of a survival advantage and risk of neurocognitive dysfunctions (level A).
• When withholding adjuvant WBRT following complete surgical resection or SRS, a close monitoring with MRI (every 3–4 mo) is 
recommended (Good Practice Point).
• When withholding adjuvant WBRT after surgical resection of brain metastases, postoperative stereotactic radiosurgery or ste-
reotactic fractionated radiotherapy to the resection cavity should be given to maintain and increase local control (level C). As the 
post-resection cavity volume is usually smaller than pre-resection metastasis volume, it is recommended to perform a postopera-
tive dedicated brain MRI for the SRS/SFRT, while the timing appears not to be relevant (Good Practice Point).
• When employing initial WBRT, a monitoring of cognitive functions with specific batteries is recommended (Good Practice Point).
• The decision regarding whether to employ SRS, SFRT, WBRT, alone or in combination, for patients with multiple brain metastases 
comes down to clinical discretion, patient preference and logistical considerations with the absolute number of brain metastases 
becoming less crucial (Good Practice Point).
• WBRT or best supportive care should be considered for patients with short life expectancy (low KPS score and/or progressive 
systemic disease) (level B).
Table 4 Recommendations regarding treatment of recurrent brain 
metastasis
• Surgery can be an option in selected patients with favorable 
prognostic factors (younger age, high performance status, 
controlled systemic disease) and accessible location or 
when a differential diagnosis between tumor regrowth and 
radionecrosis (especially following SRS) is required (level C).
• Salvage SRS following initial WBRT can be an option in 
terms of local tumor control and survival (level C).
• Multiple courses of SRS for new brain metastases after an 
initial course of SRS can represent an alternative to WBRT 
(level C).
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could occur. A superior efficacy of combination therapies 
(BRAF and MEK [mitogen/extracellular signal-regulated 
kinase] inhibitors, nivolumab and ipilimumab) is emerg-
ing in metastatic melanoma,111 but there are no data on 
brain metastases thus far.
Renal Cell Carcinoma
Some retrospective series have described responses of 
brain metastases to sunitinib,112,113 mostly in patients 
with small, asymptomatic metastases. In an open 
label EAP study, sunitinib displayed a response rate of 
12%, with PFS and OS of 5.6  months and 9.2  months, 
respectively (class  IIIb).112 In another recent retrospec-
tive series on the efficacy of targeted therapies (suni-
tinib in 41 of 65 patients), a median OS of 12.2 months 
was observed (class IV).114 Conversely, in a small phase 
II study of 16 patients with untreated brain metastases 
receiving sunitinib, 5 patients had SD only.115 A  syn-
ergism between targeted therapies and SRS has been 
suggested.116 
Supportive care: This section can be found in the 
Supplementary material.
Conclusion
Our guidelines represent the state of knowledge at the 
time of writing. The European Association of Neuro-
Oncology website will provide future updates of these 
guidelines.
Table 5 Recommendations regarding medical therapy
• Conventional chemotherapy may be the initial treatment for patients with brain metastases from chemosensitive tumors, like SCLC 
or breast cancer, especially when small and/or asymptomatic (Good Practice Point).
• No targeted agents are currently registered for the treatment of brain metastases from any solid tumors (Good Practice Point).
• Patients with brain metastases from NSCLC harboring activating EGFR mutations or ALK rearrangements can derive benefit from 
the use of specific TKIs (level C).
• Continuous HER2 blockade should be offered to patients with CNS metastases of HER2 positive breast cancer (Good Practice Point).
• Patients with brain metastases from HER2 positive breast cancer can derive benefit from the use of lapatinib, alone or associated 
with capecitabine (level C).
• Patients with melanoma and brain metastases can derive benefit from targeted agents either ipilimumab or BRAF inhibitors  
(level C).
• Patients with renal cell carcinoma and brain metastases can derive benefit from multitarget TKIs, in particular sunitinib (Good 
Practice Point).
• Overall, while SRS or WBRT remain the mainstay of initial therapy, in selected patients with asymptomatic and small brain metasta-
ses targeted agents may be a reasonable option for an upfront treatment (Good Practice Point).
• Ultimately, patients with solid tumors and brain metastases should be encouraged to participate in clinical trials with targeted 
agents, when available (Good Practice Point).
• Pausing of treatment with novel systemic agents during radiotherapy to the brain should be considered to minimize the risk of  
unexpected toxicities (Good Practice Point).
Table 6 Recommendations regarding supportive care
• For symptomatic patients, dexamethasone is the corticosteroid of choice and a twice-daily dosing is sufficient. Total daily doses 
range between 4 mg and 32 mg (Good Practice Point).
• An attempt to reduce the dose of steroids in order to minimize side effects from chronic steroid administration should be under-
taken once the maximum neurological improvement has been obtained (Good Practice Point).
• Asymptomatic patients do not need steroids, while steroids may reduce the acute or subacute side effects of WBRT or SRS (Good 
Practice Point).
• Anticonvulsants should not be prescribed prophylactically (level A).
• In patients who suffer from seizures and need a concomitant treatment with chemotherapeutics or targeted agents, enzyme-
inducing antiepileptic drugs should be avoided (level B).
• In patients with venous-thrombo-embolism (VTE), low-molecular-weight-heparin (LMWH) is effective and well tolerated for both 
initial therapy and secondary prophylaxis (level A). A duration ranging from 3 to 6 months is recommended for the anticoagulant 
treatment (Good Practice Point); however, there are some data supporting longer use in patient with active malignancies and 
those with recurrence despite therapy. Prophylaxis in patients undergoing surgery is recommended (level B recommendation).
• Bevacizumab treatment can be considered for symptomatic radionecrosis (Good Practice Point).
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